全球鐮狀細胞性貧血檢測與篩檢市場

預計到 2030 年全球鐮狀細胞性貧血檢測和篩檢市場規模將達到 7.154 億美元

全球鐮狀細胞性貧血檢測和篩檢市場規模預計在2024年為4.13億美元，到2030年將達到7.154億美元，在2024-2030年的分析期內，複合年成長率為9.6%。血紅素是本報告分析的細分市場之一，預計其複合年成長率為9.2%，到分析期結束時將達到3.383億美元。高效液相層析細分市場在分析期間的複合年成長率預計為8.1%。

美國市場規模估計為 1.125 億美元，中國市場預計複合年成長率為 13.0%

美國鐮狀性貧血檢測和篩檢市場規模預計在2024年達到1.125億美元。作為世界第二大經濟體，中國預計在2024年至2030年期間實現13.0%的複合年成長率，到2030年市場規模將達到1.448億美元。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為6.9%和8.4%。在歐洲，預計德國的複合年成長率約為7.5%。

全球鐮狀細胞性貧血檢測和篩檢市場—主要趨勢和促進因素摘要

為什麼鐮狀細胞性貧血檢測成為全球醫療保健的優先事項？了解對早期診斷日益成長的需求

隨著政府和醫療機構重視早期發現和疾病管理，鐮狀細胞性貧血的檢測和篩檢變得越來越重要。鐮狀細胞疾病 (SCD) 是一種遺傳性血液疾病，影響全球數百萬人，尤其是在非洲、中東、印度以及北美和南美部分地區等高發生率。早期診斷對於預防中風、器官損傷和劇烈疼痛等併發症至關重要。政府和醫療機構正在加強新生兒篩檢項目，以確保早期療育，從而改善患者預後並降低醫療成本。此外，婚前和產前篩檢的擴大進一步要求需要可近且準確的檢測解決方案。隨著人們對鐮狀細胞疾病認知的提高，醫療保健系統正在整合先進的篩檢技術，以促進早期發現和更好的治療方案。

技術進步如何改善鐮狀細胞疾病檢測？探索診斷準確性和可近性的創新

診斷技術的進步徹底改變了鐮狀細胞性貧血的檢測，使得更準確、更快速、更經濟的篩檢方法成為可能。血紅蛋白電泳和高效液相層析(HPLC) 等傳統臨床檢測正在與新一代診斷工具相輔相成，例如照護現場(POC) 設備、自動分子檢測和基因篩檢技術。基於 CRISPR 的基因編輯研究也開闢了識別與鐮狀細胞疾病相關的基因突變的可能性，為精準醫療方法鋪平了道路。此外，人工智慧診斷平台正在提高套件的準確性並減少假陽性和假陰性。分散式檢查選項的擴展，例如家用和社區篩檢套件，使得醫療基礎設施有限的偏遠地區更容易進行檢測。隨著檢測技術的發展，鐮狀細胞性貧血的診斷正變得更有效率、經濟實惠且在全球範圍內可及。

阻礙鐮狀細胞偵測廣泛應用的挑戰有哪些？如何應對市場壁壘和醫療保健差異

儘管檢測技術取得了進步，但鐮狀細胞性貧血篩檢的廣泛應用仍面臨若干挑戰。低收入地區有限的醫療基礎設施阻礙了診斷工具的獲取，從而限制了及時發現和治療。分子和基因篩檢方法的高成本造成了經濟負擔，並限制了服務不足人口獲得優質醫療服務的機會。此外，人們對鐮狀細胞疾病和檢測選擇的認知有限，尤其是在開發中國家，導致診斷和介入的延遲。監管障礙和各地區檢測指南不一致進一步使市場擴張複雜化，因此需要加強國際合作，以標準化篩檢項目。應對這些挑戰需要專注於醫療基礎設施、政策改革和公共衛生宣傳活動，以提高可及性和意識。

鐮狀細胞性貧血檢測市場的成長動力是什麼？關鍵擴張趨勢和醫療保健舉措

鐮狀性貧血檢測和篩檢市場的成長受到多種因素的推動，包括政府資助的篩檢計畫、分子診斷技術的進步以及醫療資金的增加。國家強制要求的新生兒篩檢在擴大早期檢測工作方面發揮關鍵作用，刺激了對先進診斷技術的投資。發展中國家鐮狀細胞鐮狀盛行率的上升進一步推動了對經濟實惠且可擴展的篩檢解決方案的需求。此外，全球衛生組織和非營利組織正在資助研究和以地區為基礎項目，以提高人們對疾病的認知並增加檢測的可及性。基因檢測服務的擴展和基於CRISPR的創新也促進了市場的成長，同時個人化醫療方法在鐮狀細胞性貧血管理中的廣泛應用也促進了市場的成長。隨著診斷技術的進步和全球改善疾病管理的努力不斷加強，鐮狀性貧血檢測市場預計將持續成長，並改善全球患者的治療效果。

部分

技術（血紅素、高效液相層析、就地檢驗、其他檢測）；年齡層（1 歲以下、25-60 歲、其他）；產業類型（政府實驗室、私人實驗室、企業實驗室、PPP）

受訪公司範例

• Alpha Laboratories
• ASI（Analytical Services International）
• Atlas Medical
• Beam Therapeutics
• BioMedomics Inc.
• Bio-Rad Laboratories, Inc
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• Cigna
• CRISPR Therapeutics
• Daktari Diagnostics
• Emmaus Life Sciences, Inc.
• Fisher Scientific
• Functional Fluidics
• Global Blood Therapeutics, Inc.（Pfizer Inc.）
• Hemex Health
• HEMEX HEALTH
• HemoTypeSC
• Imara Inc.
• KovaDx
• Laboratory Corporation of America Holdings
• LABS Inc.
• Mayo Clinic
• Modus Therapeutics
• Novartis AG
• Pfizer Inc.
• Quest Diagnostics
• Sanofi SA
• Silver Lake Research Corporation
• STRECK, INC

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地以及進出口情況（成品和原始OEM）預測其競爭地位的變化。這種複雜多變的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 比賽

Global Sickle Cell Anemia Testing and Screening Market to Reach US$715.4 Million by 2030

The global market for Sickle Cell Anemia Testing and Screening estimated at US$413.0 Million in the year 2024, is expected to reach US$715.4 Million by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Hemoglobin, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$338.3 Million by the end of the analysis period. Growth in the High-Performance Liquid Chromatography segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$112.5 Million While China is Forecast to Grow at 13.0% CAGR

The Sickle Cell Anemia Testing and Screening market in the U.S. is estimated at US$112.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$144.8 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Sickle Cell Anemia Testing and Screening Market - Key Trends & Drivers Summarized

Why Is Sickle Cell Anemia Testing Becoming a Global Healthcare Priority? Understanding the Rising Demand for Early Diagnosis

Sickle cell anemia testing and screening have gained increasing importance as governments and healthcare institutions prioritize early detection and disease management. Sickle cell disease (SCD) is a genetic blood disorder that affects millions worldwide, particularly in regions with high prevalence rates, such as Africa, the Middle East, India, and parts of North and South America. Early diagnosis is crucial in preventing complications such as stroke, organ damage, and severe pain crises. Governments and health organizations have ramped up newborn screening programs to ensure early intervention, leading to improved patient outcomes and reduced healthcare costs. Additionally, the expansion of premarital and prenatal screening initiatives has further reinforced the need for accessible and accurate testing solutions. As awareness of sickle cell disease grows, healthcare systems are integrating advanced screening technologies to facilitate early identification and better treatment planning.

How Are Technological Advancements Improving Sickle Cell Testing? Exploring Innovations in Diagnostic Accuracy and Accessibility

Advancements in diagnostic technology have revolutionized sickle cell anemia testing, enabling more precise, rapid, and cost-effective screening methods. Traditional laboratory tests, such as hemoglobin electrophoresis and high-performance liquid chromatography (HPLC), have been complemented by next-generation diagnostic tools, including point-of-care (POC) testing devices, automated molecular assays, and genetic screening techniques. CRISPR-based gene-editing research has also opened possibilities for identifying genetic mutations associated with sickle cell disease, paving the way for precision medicine approaches. Furthermore, AI-powered diagnostic platforms are enhancing interpretation accuracy, reducing false positives and negatives. The expansion of decentralized testing options, including at-home and community-based screening kits, has made testing more accessible in remote areas with limited healthcare infrastructure. As testing technology continues to evolve, sickle cell anemia diagnostics are becoming more efficient, affordable, and globally accessible.

What Challenges Are Hindering the Adoption of Sickle Cell Testing? Addressing Market Barriers and Healthcare Disparities

Despite the advancements in testing technology, several challenges limit the widespread adoption of sickle cell anemia screening. Limited healthcare infrastructure in low-income regions has hindered the availability of diagnostic tools, restricting access to timely detection and treatment. The high costs associated with molecular and genetic screening methods also pose affordability concerns, making it difficult for underprivileged populations to access quality care. Additionally, inadequate awareness about sickle cell disease and testing options has led to underdiagnosis and delayed interventions, particularly in developing nations. Regulatory hurdles and inconsistent testing guidelines across different regions further complicate market expansion, requiring greater international collaboration to standardize screening programs. Addressing these challenges will require targeted investments in healthcare infrastructure, policy reforms, and public health campaigns to increase accessibility and awareness.

What’s Driving the Growth of the Sickle Cell Anemia Testing Market? Identifying Key Expansion Trends and Healthcare Initiatives

The growth in the sickle cell anemia testing and screening market is driven by several factors, including government-backed screening programs, advancements in molecular diagnostics, and increased healthcare funding. National newborn screening mandates have played a crucial role in expanding early detection efforts, prompting investments in advanced diagnostic technologies. The rising prevalence of sickle cell disease in developing countries has further accelerated the demand for affordable and scalable screening solutions. Additionally, global health organizations and non-profit initiatives are funding research and community-based programs to enhance disease awareness and testing accessibility. The expansion of genetic testing services and CRISPR-based innovations has also contributed to market growth, as personalized medicine approaches gain traction in managing sickle cell disease. With ongoing advancements in diagnostics and increasing global efforts to improve disease management, the market for sickle cell anemia testing is expected to witness sustained growth, improving patient outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Sickle Cell Anemia Testing and Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests, Other Tests); Age Group (Below 1 yr, 25 - 60 yrs, Others); Sector Type (Government Labs, Private Labs, Corporate Labs, PPP)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Alpha Laboratories
• ASI (Analytical Services International)
• Atlas Medical
• Beam Therapeutics
• BioMedomics Inc.
• Bio-Rad Laboratories, Inc
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• Cigna
• CRISPR Therapeutics
• Daktari Diagnostics
• Emmaus Life Sciences, Inc.
• Fisher Scientific
• Functional Fluidics
• Global Blood Therapeutics, Inc. (Pfizer Inc.)
• Hemex Health
• HEMEX HEALTH
• HemoTypeSC
• Imara Inc.
• KovaDx
• Laboratory Corporation of America Holdings
• LABS Inc.
• Mayo Clinic
• Modus Therapeutics
• Novartis AG
• Pfizer Inc.
• Quest Diagnostics
• Sanofi SA
• Silver Lake Research Corporation
• STRECK, INC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Sickle Cell Anemia Testing and Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Awareness of Hereditary Blood Disorders Throws the Spotlight on Sickle Cell Screening Programs
  • Expansion of Neonatal and Prenatal Genetic Screening Drives Early Diagnosis of Sickle Cell Anemia
  • OEM Innovation in Point-of-Care Diagnostic Devices Enhances Access in Low-Infrastructure Settings
  • Growth in National Health Missions and Public Health Campaigns Spurs Universal Screening Mandates
  • OEM Development of Cost-Effective, High-Accuracy Lateral Flow Assays Supports Rural Deployment
  • Rising Birth Prevalence in Sub-Saharan Africa, India, and Middle East Expands Addressable Market
  • OEM Integration of Multiplex Testing Platforms Improves Detection Accuracy and Workflow Efficiency
  • Regulatory Support for Newborn Screening and Carrier Testing Strengthens Diagnostic Uptake
  • Surge in Gene Therapy Clinical Trials Promotes Pre-Treatment Genotyping and Risk Stratification
  • OEM Collaboration With Blood Banks and Pediatric Hospitals Enhances Institutional Testing Infrastructure
  • Expansion of Community-Based Outreach Models Encourages Voluntary Screening and Genetic Counseling
  • OEM Focus on Mobile Diagnostic Vans and Home Collection Models Expands Reach in Underserved Regions
  • Increasing Use of Telemedicine for Genetic Interpretation and Counseling Supports Screening Continuity
  • OEM Investment in Digital Records and National Screening Registries Enhances Patient Tracking
  • Rising Support From NGOs and Global Health Agencies Drives Free or Subsidized Testing Programs
  • OEM Partnerships With Pharma Companies Enable Companion Diagnostics in Targeted SCD Treatments
  • Growth in Workplace and School-Based Screening Initiatives Supports Preventive Health Policies
  • OEM Innovation in Saliva and Dried Blood Spot Sampling Improves Testing in Infants and Adolescents
  • Shift Toward Carrier Identification and Premarital Screening Programs Promotes Informed Reproductive Choices
  • Focus on Equity, Inclusion, and Stigma Reduction Enhances Public Acceptance of Mass Screening Campaigns
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Sickle Cell Anemia Testing and Screening Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Hemoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Hemoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Hemoglobin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for High-Performance Liquid Chromatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for High-Performance Liquid Chromatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for High-Performance Liquid Chromatography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Point-of-Care Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Corporate Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Corporate Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Corporate Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for PPP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for PPP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for PPP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Government Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Government Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Government Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Private Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Private Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Private Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Below 1 yr by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Below 1 yr by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Below 1 yr by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for 25 - 60 yrs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for 25 - 60 yrs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for 25 - 60 yrs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• JAPAN
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• CHINA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• EUROPE
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• FRANCE
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• GERMANY
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• INDIA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• AFRICA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030

IV. COMPETITION